<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="34035">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02663518</url>
  </required_header>
  <id_info>
    <org_study_id>TTI-621-01</org_study_id>
    <nct_id>NCT02663518</nct_id>
  </id_info>
  <brief_title>A Trial of TTI-621 for Patients With Hematologic Malignancies</brief_title>
  <official_title>A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621, a Novel Biologic Targeting CD47, in Subjects With Relapsed or Refractory Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Trillium Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Trillium Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter, open-label, Phase 1a/1b trial of TTI-621 in subjects with relapsed or
      refractory hematologic malignancies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a trial of TTI-621 in subjects with relapsed or refractory hematologic malignancies
      that will be conducted in 2 parts. In the dose Escalation Phase, subjects with lymphoma will
      be enrolled in sequential dose cohorts to receive TTI-621 to characterize safety,
      tolerability, pharmacokinetics, and the maximum-tolerated dose (MTD). In the Expansion
      Phase, subjects with a variety of hematologic malignancies will be treated at the optimal
      dose to further define safety and to characterize efficacy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
    <masking_description>Open label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting Toxicity (DLT)</measure>
    <time_frame>18 months</time_frame>
    <description>Number of participants with a DLT</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">186</enrollment>
  <condition>Hematologic Malignancies</condition>
  <arm_group>
    <arm_group_label>TTI-621</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Escalation Phase will include multiple doses of TTI-621 followed by the Expansion Phase during which one or more selected dose levels of TTI-621 will be tested.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TTI-621</intervention_name>
    <description>TTI-621 (SIRPαFc) is a soluble recombinant fusion protein created by directly linking the sequences encoding the N-terminal CD47 binding domain of human SIRPα with the Fc domain of human immunoglobulin (IgG1). TTI-621 acts by binding human CD47 and preventing it from delivering an inhibitory &quot;do not eat&quot; (antiphagocytic) signal to macrophages.</description>
    <arm_group_label>TTI-621</arm_group_label>
    <other_name>TTI-621 (SIRPαFc)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically documented advanced lymphoma (escalation) advanced hematologic
             malignancies (expansion) with evaluable disease.

          2. Adequate hematologic status

          3. Relapsed or refractory disease after at least 1 prior systemic treatment for the
             primary malignancy and not a candidate for other curative treatment.

          4. Adequate coagulation function

          5. Adequate hepatic function

          6. Adequate renal function

        Exclusion Criteria:

          1. Known central nervous system disease involvement.

          2. Allogeneic transplant within 100 days prior to the planned start of treatment or
             subjects with active graft-vs-host disease with the exception of Grade 1 skin
             involvement.

          3. History of hemolytic anemia or bleeding diathesis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Sievers, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Trillium Therapeutics Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Meghan Irwin</last_name>
    <email>meghan@trilliumtherapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Yuan Tan</last_name>
      <phone>626-256-4673</phone>
      <phone_ext>89948</phone_ext>
      <email>ytan@coh.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Colorado Blood Cancer Institute</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>877-691-7274</phone>
      <email>asksarah@sarahcannon.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carol Fairchild</last_name>
      <email>fairchild.carol@mayo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Ansell</last_name>
      <phone>855-776-0015</phone>
      <email>ansell.stephen@mayo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia Univeristy</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renee Lichtenstein</last_name>
      <phone>212-326-5732</phone>
      <email>Rl2619@cumc.columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Lesokhin</last_name>
      <phone>646-888-4593</phone>
      <email>lesokhia@mskcc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anjali Advani</last_name>
      <email>ADVANIA@ccf.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>877-691-7274</phone>
      <email>asksarah@sarahcannon.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Washington - Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cody Hammer</last_name>
      <email>chammer@seattlecca.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>British Columbia Cancer Agency</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1H6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Diego Villa</last_name>
      <phone>604-877-6000</phone>
      <email>dvilla@bccancer.bc.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Center</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nishita Parekh</last_name>
      <phone>416-581-7896</phone>
      <email>Nishita.Parekh@uhn.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clincancerres.aacrjournals.org/content/clincanres/early/2017/01/09/1078-0432.CCR-16-1700.full.pdf</url>
    <description>TTI-621: a novel innate immune checkpoint inhibitor</description>
  </link>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 13, 2017</lastchanged_date>
  <firstreceived_date>January 19, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
